• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.29%

    PDL BioPharma, Inc. (PDLI)

    -NasdaqGS
    7.63 Up 0.06(0.79%) 4:00PM EST
    |After Hours : 7.63 0.00 (0.00%) 4:30PM EST
    Add to Portfolio
    ProfileGet Profile for:
    PDL BioPharma, Inc.
    932 Southwood Boulevard
    Incline Village, NV 89451
    United States - Map
    Phone: 775-832-8500
    Fax: 775-832-8501
    Website: http://www.pdl.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:10

    Business Summary 

    PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on PDL BioPharma, Inc.

    Corporate Governance 
    PDL BioPharma, Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 3. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 4; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. John P. McLaughlin J.D., 63
    Chief Exec. Officer, Pres, Director and Member of Litigation Committee
    2.69M0.00
    Mr. Peter S. Garcia , 53
    Chief Financial Officer and VP
    603.00K0.00
    Mr. David Montez CPA, 41
    Chief Accounting Officer and Controller
    177.00K0.00
    Mr. Christopher L. Stone J.D., 51
    VP, Gen. Counsel and Sec.
    1.23M0.00
    Mr. Danny J. Hart Jr., J.D., 39
    VP of Bus. Devel.
    855.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders